Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Feb 22:11:2042098620905976.
doi: 10.1177/2042098620905976. eCollection 2020.

Secukinumab-induced Raynaud's phenomenon: first report in the literature

Senol Kobak  1
Affiliations
Case Reports

Secukinumab-induced Raynaud's phenomenon: first report in the literature

Senol Kobak. Ther Adv Drug Saf. .

Abstract

Secukinumab is an IL-17A antagonist that has proven efficacy in the treatment of patients with ankylosing spondylitis (AS) and psoriatic arthritis. Side effects of the drug include infections, skin rashes, and allergic reactions. Raynaud's phenomenon (RP), a vasospastic syndrome and an important feature of different connective tissue diseases, is not an expected finding in AS patients. This article reports the development of secukinumab-related RP in a 35-year-old female patient with AS. Treatment with secukinumab was continued and RP was treated with low-dose aspirin and a calcium-channel blocker.

Keywords: Raynaud’s phenomenon; ankylosing spondylitis; secukinumab.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The author declares that there is no conflict of interest.

Figures

Figure 1.
Figure 1.
Raynaud’s phenomenon (three color changes) of the hand after secukinumab injection.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Navarro-Compán V. An update on diagnosis and classification of axial spondyloarthritis. Curr Rheumatol Rep 2019; 21: 39. - PubMed
    1. So A, Inman RD. An overview of biologic disease-modifying antirheumatic drugs in axial spondyloarthritis and psoriatic arthritis. Best Pract Res Clin Rheumatol 2018; 32: 453–471. - PubMed
    1. Blair HA. Secukinumab: a review in ankylosing spondylitis. Drugs 2019; 79: 433–443. - PMC - PubMed
    1. Wendling D, Verhoeven F, Prati C. Anti-IL-17 monoclonal antibodies for the treatment of ankylosing spondylitis. Expert Opin Biol Ther 2019; 19: 55–64. - PubMed
    1. Lubrano E, Perrotta FM. Secukinumab for ankylosing spondylitis and psoriatic arthritis. Ther Clin Risk Manag 2016; 12: 1587–1592. - PMC - PubMed

Publication types